自体细胞因子诱导的杀伤细胞治疗肺癌患者的临床疗效观察  

Effect of autologous cytokine induced killer cell therapy in patients with lung cancer

作　　者：张丽坤[1] 曹峰林[1] 

机构地区：[1]哈尔滨医科大学附属第一医院血液肿瘤研究所,哈尔滨150001

出　　处：《实用肿瘤学杂志》2015年第4期342-346,共5页Practical Oncology Journal

摘　　要：目的：评估CIK细胞（ Cytokine－induced killer cell，CIK）治疗晚期肺癌的临床疗效。方法从32例晚期肺癌患者外周血中分离出单个核细胞（ PBMC），加入含有IFN－γ、IL－2和抗CD3单抗等细胞因子的培养基进行培养，培养15天后分次回输给患者。观察患者治疗前后瘤体变化、免疫指标变化、临床症状的改善情况和毒副反应，进行临床疗效评价。结果32例接受CIK治疗的患者临床症状明显改善，毒副反应轻。免疫表型分析结果显示CD3／CD4共表达34．4％，CD3／CD8共表达68．2％，CD3／CD56共表达13．7％。 CIK细胞回输后约15天CT影像显示胸腔积液减少。临床疗效评价有效率为56．0％，疾病控制率（ CR＋PR＋SD）为84．3％。结论 CIK细胞免疫疗法可以改善肺癌患者免疫功能，抑制肿瘤生长，改善临床症状，改善生存质量。Objective To evaluate the clinical effect of cytokine induced killer cellular immunotherapies （ CIK） on the patients with advanced lung cancer.Methods Peripheral blood mononuclear cell from 32 cases of patients with advanced lung cancer were isolated.Cells were cultured in DMEM supplemented with IFN-γ,IL-2,anti-CD3 monoclonal antibody and other cytokines,and transfused back into the patients in several times after 15 days of culture.Subsequently,we observed the size of tumor,the change of immunologic function by CIK treat-ment,the status of clinical symptoms,and the toxic and side effect.The clinical curative effect was also evaluated. Results The symptoms in 32 patients who received CIK therapy were reduced,and the side effects were light. Immunophenotype analysis showed that CD3 /CD4 coexpression were found in 34.4%patients,CD3 /CD8 co-expression in 68.2%,and CD3 /CD56 co-expression in 13.7% patients.CT images about 15 days after CIK cell transfusion showed that pleural effusion were decreased.Clinical evaluation effective rate was 56.0%,and disease control rate（ CR ＋PR ＋SD） was 84.3%.Conclusion CIK cell immunotherapies of cancer patients can improve immunologic function of cancer patients and inhibit tumor growth and relieve the clinical symptom of patients,and improve the quality of life.

关 键 词：CIK细胞 肺癌 细胞免疫 

分 类 号：R456[医药卫生—治疗学] R457.2[医药卫生—临床医学]